SCHEMBL20123075

SCHEMBL20123075

Cn1cc(-c2cc(Cl)cc3c4ccncc4n(CC4CC4)c23)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.45
KCNH2 Q12809 1/20 0.45
NFATC1 O95644 1/20 0.41
GSK3B P49841 1/20 0.41
ROCK2 O75116 1/20 0.39
PTGER4 P35408 1/20 0.38
MAPT P10636 2/20 0.35
DRD2 P14416 1/20 0.35
CRHR1 P34998 1/20 0.35
RET P07949 1/20 0.35
PDK2 Q15119 1/20 0.35
TYRO3 Q06418 1/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
INCENP Q9NQS7 1/20 0.34
TPX2 Q9ULW0 1/20 0.34
METAP2 P50579 1/20 0.34
CCNC P24863 2/20 0.33
CDK8 P49336 2/20 0.33
KDM4C Q9H3R0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664172 1.00 DYRK1A (0.45) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL30664200 0.86 KCNH2 (0.49) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL20122885 0.86 KCNH2 (0.49) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL20122886 0.85 DYRK1A (0.46) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL30664155 0.84 ROCK2 (0.45) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL20122876 0.84 ROCK2 (0.45) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL20122996 0.84 PDK2 (0.41) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL30664226 0.84 PDK2 (0.41) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL20122884 0.83 L3MBTL1 (0.41) DYRK1AKCNH2NFATC1GSK3BROCK2
SCHEMBL29756304 0.83 L3MBTL1 (0.41) DYRK1AKCNH2NFATC1GSK3BROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885KCNH2 3028/4885NFATC1 1647/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885KCNH2 3028/4885NFATC1 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.